case_images: PMC10794777_01
case_images: Computed tomography imaging demonstrating response in segment 2 and segment 8 lesions post cycle 4 and post cycle 8 of combination atezolizumab/bevacizumab.
case_images: fonc-13-1279501-g001.jpg
case_images: PMC10794777_01_fonc-13-1279501-g001.jpg
case_images: f1
case_images: Terminology Criteria for Adverse Events. CT scan after 4 cycles showed stable disease with a trend towards response.  Figure 1  shows the trend of the segment 2 lesion and the segment 8 lesion over the time on combination atezolizumab and bevacizumab therapy. The segment 8 lesion responded particularly well, demonstrating a 40% decrease in size from 20 mm to 12 mm between April 2021 and April 2022, with stable disease following this.
case_images: Chart showing the patient's blood pressure readings over time for the duration of combination atezolizumab/bevacizumab treatment. atezo/beva, atezolizumab/bevacizumab.
case_images: fonc-13-1279501-g002.jpg
case_images: PMC10794777_02_fonc-13-1279501-g002.jpg
case_images: f2
case_images: As seen by  Figure 2 , blood pressure was highly variable and may have been due to variations in total body fluid with dialysis.
case_images: Timeline of the patient's clinical course with key events, complications and medication changes. HCC, hepatocellular carcinoma; Cx, complications; TACE, transarterial chemoembolization; MRI, magnetic resonance image; CT, computed tomography; PR, partial response; SD, stable disease; OGD, oesophagogastroduodenoscopy; PHG, portal hypertensive gastropathy; PD, disease progression; SACT, systemic anticancer treatment.
case_images: fonc-13-1279501-g003.jpg
case_images: PMC10794777_01_fonc-13-1279501-g003.jpg
case_images: f3
case_images: Subsequently, atezolizumab has been stopped and the focus of care has shifted to best supportive care.  Figure 3  is a summary infographic of the patient's clinical timeline.
case_images: PMC10794777_02
case_images: Chart showing the patient's blood pressure readings over time for the duration of combination atezolizumab/bevacizumab treatment. atezo/beva, atezolizumab/bevacizumab.
case_images: fonc-13-1279501-g002.jpg
case_images: PMC10794777_02_fonc-13-1279501-g002.jpg
case_images: f2
case_images: As seen by  Figure 2 , blood pressure was highly variable and may have been due to variations in total body fluid with dialysis.